← All trials
NCT04974398
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Oct 31, 2025
- First posted
- Jul 23, 2021
- Last posted
- Aug 30, 2021
- Enrollment
- 278
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.